$BMY Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

on June 18, 2021 News and Tags: , , , with 0 comments
Time:
9:34 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

on June 17, 2021 News and Tags: , , , with 0 comments
Time:
6:30 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb Announces Dividend

on June 17, 2021 News and Tags: , , , with 0 comments
Time:
4:16 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia

on June 11, 2021 News and Tags: , , , , , , , with 0 comments
Time:
3:00 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience

on June 10, 2021 News and Tags: , , , with 0 comments
Time:
4:16 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021

on June 10, 2021 News and Tags: , , , with 0 comments
Time:
7:05 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

on June 8, 2021 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference

on June 4, 2021 News and Tags: , , , with 0 comments
Time:
6:59 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced

on June 3, 2021 News and Tags: , , , with 0 comments
Time:
5:01 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1

on May 27, 2021 News and Tags: , , , with 0 comments
Time:
4:13 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY The Bristol Myers Squibb Foundation Announces First Global Cancer Disparities Grants in Brazil

on May 25, 2021 News and Tags: , , , with 0 comments
Time:
5:00 AM
Symbol:
BMY
Source:
3BL Media: Corporate Social Responsibility, Energy and Health News
Read more

$BMY Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia (ozanimod) Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative Colitis

on May 23, 2021 News and Tags: , , , with 0 comments
Time:
11:35 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Co

on May 21, 2021 News and Tags: , , , with 0 comments
Time:
4:16 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Che

on May 20, 2021 News and Tags: , , , with 0 comments
Time:
1:26 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$AGEN Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors

on May 20, 2021 News and Tags: , , , , , , , with 0 comments
Time:
6:59 AM
Symbol:
AGEN
Source:
Business Wire News Releases
Read more

$BMY Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 Chec

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
5:00 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
5:00 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BLUE Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel)

on May 19, 2021 News and Tags: , , , , , , , with 0 comments
Time:
5:00 PM
Symbol:
BLUE
Source:
Business Wire News Releases
Read more

$BMY Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previous

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
5:00 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$BMY Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

on May 19, 2021 News and Tags: , , , with 0 comments
Time:
5:00 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more